盐酸多奈哌齐片联合氯氮平分散片治疗阿尔茨海默病伴行为障碍的临床研究

发布时间：2018-09-17 19:04

【摘要】：目的观察盐酸多奈哌齐片联合氯氮平分散片治疗阿尔茨海默病伴行为障碍的临床疗效及安全性。方法将80例阿尔茨海默病伴行为障碍患者随机分为对照组40例和试验组40例。对照组予以盐酸多奈哌齐5 mg,服用1个月后可增至10 mg,qd,晚上睡前口服;试验组在对照组治疗的基础上,予以氯氮平起始剂量25 mg,在前2~3周内缓慢加量,每4~5天增加25~50 mg,直到200mg·d~(-1),晚上睡前口服。2组患者均治疗6个月。比较2组患者的临床疗效、阿尔茨海默病行为病理评定量表(BEHAVE-AD)评分,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为87.50%(35/40例)和55.00%(22/40例),BEHAVE-AD评分分别为(4.44±1.95)和(8.86±2.47)分,差异均有统计学意义(均P0.05)。2组患者的药物不良反应主要有恶心、口干、头晕、嗜睡、体重增加和便秘,且试验组和对照组的药物不良反应发生率分别为40.00%和37.50%,差异无统计学意义(P0.05)。结论盐酸多奈哌齐片联合氯氮平分散片治疗阿尔茨海默病伴行为障碍的临床疗效确切,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the efficacy and safety of Donepezil hydrochloride and clozapine dispersible tablets in the treatment of Alzheimer's disease with behavioral disorders. Methods 80 patients with Alzheimer's disease with behavioral disorder were randomly divided into control group (n = 40) and trial group (n = 40). The control group was treated with Donepezil hydrochloride for 5 mg, for 1 month, and the control group was given clozapine at the initial dose of 25 mg, for 10 mg,qd, at night before bedtime, and the initial dose of clozapine was added slowly within the first 2 weeks 3 weeks. Every 4 days, 25 mg, and 50 mg, were increased until 200mg d-1. The patients in group 2 were treated for 6 months before bedtime. The clinical efficacy, BEHAVE-AD score and adverse drug reaction were compared between the two groups. Results after treatment, the total effective rates of the trial group and the control group were 87.50% (35 / 40) and 55.00% (22 / 40) respectively. The scores of BEHAVE-AD were (4.44 卤1.95) and (8.86 卤2.47), respectively. Weight gain and constipation, and the incidence of adverse drug reactions in the test group and the control group were 40.00% and 37.50 respectively, the difference was not statistically significant (P0.05). Conclusion Donepezil hydrochloride combined with clozapine dispersible tablets is effective in the treatment of Alzheimer's disease with behavioral disorders and does not increase the incidence of adverse drug reactions.
【作者单位】：重庆三峡医药高等专科学校附属医院神经内科;
【基金】：国家自然科学基金资助项目(81100948)
【分类号】：R749.16

【相似文献】